[PtMe3(μ-pyrimidine-2-thione-κS(1-))]2 | 913544-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: [PtMe3(μ-pyrimidine-2-thione-κS(1-))]2
• 英文别名: [PtMe3(μ-pymt-κS(1-))]2
• CAS: 913544-05-5
• 化学式: C₁₄H₂₄N₄Pt₂S₂
• 分子量: 702.663
• InChiKey: JPNZEXRVHHKTOJ-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  sodium pyrimidine-2-thiolate 、 三甲基碘化铂 以 甲醇 、 二氯甲烷 为溶剂， 以52%的产率得到[PtMe3(μ-pyrimidine-2-thione-κS(1-))]2
  参考文献：
  名称：

  Synthesis, structures and in vitro cytotoxicity studies of platinum(IV) complexes with N,S and S,S heterocyclic ligands

  摘要：

  Reactions of [(PtMe3I)(4)] (2) with the sodium salts of the N,S and S,S heterocycles S-DH (pyridine-2-thione, pytH; pyrimidine-2-thione, pymtH; thiazoline-2-thione, tztH; thiophene-2-thiol, tptH) resulted in the formation of the dinuclear complexes [(PtMe3)(2)(mu-D)(2)] (S-D = pyt, 3; pymt, 4; tzt, 5) and the tetranuclear complex [(PtMe3)(4)(mu(3)-tpt)(4)] (6), respectively. Single crystal X-ray diffraction analyses of 3 and 4 exhibited dinuclear complexes having a central [Pt-2(mu-S)(2)] core. The platinum atoms are octahedrally coordinated by three methyl ligands and the bridging 1 kappa N,1:2 kappa S-2 heterocyclic ligands. The two heterocyclic rings are face-to-face (cis) arranged, indicating stabilization through pi-pi stacking. The X-ray diffraction analysis of 6 confirmed a tetranuclear [Pt4S4] heterocubane structure. Each platinum atom is distorted octahedrally coordinated by three methyl ligands in facial arrangement and three mu(3)-bridging sulfur atoms. DFT calculations exhibited that the formation of the tetranuclear complex 6 can be mainly attributed to the weak coordination tendency of the thiophene S atoms of the tpt ligands to the trimethylplatinum(IV) unit. In vitro cytotoxic studies of the complexes 3-5 using five different tumor cell lines (8505C, A253, A549, A2780, DLD-1) revealed moderate to high cytotoxic activities. The most active compound is [(PtMe3)(2)(mu-tzt)(2)] (5) with IC50 values of 0.5-1.2 mu M on investigated cell lines, which is comparable to cisplatin or even better. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2009.08.004

文献信息

• Synthesis and characterization of platinum(IV) complexes with N,S and S,S heterocyclic ligands
  作者：Cornelia Vetter、Christoph Wagner、Jürgen Schmidt、Dirk Steinborn

  DOI：10.1016/j.ica.2006.06.007

  日期：2006.10

  The reactions of [PtMe3(OAc)(bpy)] (4) with the NS and S,S containing heterocycles, pyrimidine-2-thione (pymtH), pyridine-2-thi-one (pytH), thiazoline-2-thione (tztH) and thiophene-2-thiol (tptH), resulted in the formation of the monomeric complexes [PtMe3(D SKS)(bpy)] (mu-D s = pymt, 5; pyt, 6; tzt, 7; tpt, 8), where the heterocyclic ligand is coordinated via the exocyclic sulfur atom. In contrast, in the reactions of [PtMe3(OAc)(Me2CO)(x)](3, x = 1 or 2) with pymtH, pytH, tztH and tptH dimeric complexes [PtMe3(mu-D S)}(2)] (mu-D s = pymt, 9; pyt, 10; tzt, 11) and the tetrameric complex [PtMe3(mu(3)-tpt-kappa S)}(4)] (12), respectively, were formed. The complexes were characterized by microanalyses, H-1 and C-13 NMR spectroscopy and negative ESI-MS (12) measurements. Single-crystal X-ray diffraction analysis of [PtMe3(pymt-kappa S)(bpy)] (5) exhibited a conformation where the pymt ligand lies nearly perpendicular to the complex plane above the bpy ligand that was also confirmed by quantum chemical calculations on the DFT level of theory. (c) 2006 Elsevier B.V. All rights reserved.